CLAIMS


What is claimed is:



A chimeric peptide comprising an opioid receptor binding moiety and a nociceptive receptor binding moiety.

- 2. The peptide of claim 1, wherein said peptide induces analgesia when administered to a mammal.
- 3. The peptide of claim 1, wherein said opioid receptor binding moiety binds to an opioid receptor selected from the group consisting of the μ receptor, the δ receptor and the κ receptor.
- 4. The peptide of claim 3, wherein the opioid receptor is the μ receptor.
- 5. The peptide of claim 4, wherein the nociceptive receptor is the NK₁ receptor.
- 6. The peptide of claim 1, wherein said peptide comprises is a plurality of opioid receptor binding moieties.
- 7. The peptide of claim 1, wherein said peptide comprises a plurality of nociceptive receptor binding moieties.
- 8. The peptide of claim 6, wherein said pertide comprises a plurality of nociceptive receptor binding moieties.
- 9. The peptide of claim 1, wherein the opioid receptor binding moiety is selected from the group consisting of SEQ ID NOs: 1-20 and 44.
- 10. The peptide of claim 1, wherein the nociceptive receptor binding moiety is selected from the group consisting of SEQ ID NOs: 21-40 and 41.

- 11. The peptide of claim 6, wherein the plurality of opioid receptor binding moieties is selected from the group consisting of SEQ ID NOs: 1-20 and 21.
- 12. The peptide of claim 7, wherein the plurality of nociceptive receptor binding moieties is selected from the group consisting of SEQ ID NOs: 21-40 and 41.
- 13. The peptide of claim 1, wherein the nociceptive moiety is selected from the group consisting of Substance P, Substance P fragments, and Substance P derivatives.
- 14. The peptide of claim 1, wherein said peptide comprises a D-amino acid.
- 15. The peptide of claim 5, wherein the opioid receptor binding moiety is selected from the group consisting of endomorphin 1 and endomorphin 2 and the nociceptive receptor binding moiety is a fragment of Substance P.
- 16. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable diluent.
- 17. The pharmaceutical composition of claim 16, further comprising an adjuvant.
- 18. A method of treating pain in a mammal, said method comprising administering to said mammal a peptide comprising an opioid receptor binding moiety and a nociceptive receptor binding moiety in an amount sufficient to induce analgesia in said mammal.
- 19. The method of claim 18, wherein said opioid receptor binding moiety binds to an opioid receptor selected from the group consisting of the μ , δ and κ receptors.
- 20. The method of claim 18, wherein the nociceptive receptor binding moiety binds to NK₁.



22. The method of claim 18, wherein the peptide is administered with a solubilizing agent.

23. The method of claim 22, wherein the solubilizing agent is cyclodextran.

.